Read this company snapshot
Daily valuation snapshot
Design Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $11.65
- Market capitalization (USD)
- $729,076,234.15
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.61
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research DSGN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research DSGN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing DSGN with another company.
| Daily close (USD) | $11.65 |
| Market capitalization (USD) | $729,076,234.15 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.61 |
No matching rows. Clear the filter to see all records.
Read DSGN's valuation metrics
Company size
Design Therapeutics, Inc. Common Stock's recorded market capitalization is $729,076,234.15. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
DSGN's recorded price-to-book ratio is 3.61. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Design Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about DSGN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow DSGN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.